|
|
| [Code of Federal Regulations] |
| [Title 21, Volume 9] |
| [CITE: 21CFR1302] |
TITLE 21--FOOD AND DRUGS CHAPTER II--DRUG ENFORCEMENT ADMINISTRATION DEPARTMENT OF JUSTICE
| |
| PART 1302 | LABELING AND PACKAGING REQUIREMENTS FOR CONTROLLED SUBSTANCES |
|
|
|
|
Sec. 1302.01 Scope of part 1302.
|
|
Requirements governing the labeling and packaging of controlled substances pursuant to sections 1305 and 1008(d) of the Act (21 U.S.C. 825 and 958(d)) are set forth generally by those sections and specifically by the sections of this part.
[36 FR 13386, July 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973]
|
|
|
Sec. 1302.02 Definitions.
|
|
Any term contained in this part shall have the definition set forth in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
[62 FR 13958, Mar. 24, 1997]
|
|
|
Sec. 1302.03 Symbol required; exceptions.
|
|
(a) Each commercial container of a controlled substance (except for a controlled substance excepted by the Administrator pursuant to § 1308.31 of this chapter) shall have printed on the label the symbol designating the schedule in which such controlled substance is listed. Each such commercial container, if it otherwise has no label, must bear a label complying with the requirement of this part.
(b) Each manufacturer shall print upon the labeling of each controlled substance distributed by him the symbol designating the schedule in which such controlled substance is listed.
(c) The following symbols shall designate the schedule corresponding thereto:
| Schedule
|
|
|---|
| Schedule I | CI or C-I.
| | Schedule II | CII or C-II.
| | Schedule III | CIII or C-III.
| | Schedule IV | CIV or C-IV.
| | Schedule V | CV or C-V. |
The word "schedule" need not be used. No distinction need be made between narcotic and nonnarcotic substances.
(d) The symbol is not required on a carton or wrapper in which a commercial container is held if the symbol is easily legible through such carton or wrapper.
(e) The symbol is not required on a commercial container too small or otherwise unable to accommodate a label, if the symbol is printed on the box or package from which the commercial container is removed upon dispensing to an ultimate user.
(f) The symbol is not required on a commercial container containing, or on the labeling of, a controlled substance being utilized in clinical research involving blind and double blind studies.
[36 FR 7785, Apr. 24, 1971, as amended at 36 FR 18731, Sept. 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973]
|
|
|
Sec. 1302.04 Location and size of symbol on label and labeling.
|
|
The symbol shall be prominently located on the label or the labeling of the commercial container and/or the panel of the commercial container normally displayed to dispensers of any controlled substance. The symbol on labels shall be clear and large enough to afford easy identification of the schedule of the controlled substance upon inspection without removal from the dispenser's shelf. The symbol on all other labeling shall be clear and large enough to afford prompt identification of the controlled substance upon inspection of the labeling.
[62 FR 13958, Mar. 24, 1997]
|
|
|
Sec. 1302.05 Effective dates of labeling requirements.
|
|
All labels on commercial containers of, and all labeling of, a controlled substance which either is transferred to another schedule or is added to any schedule shall comply with the requirements of § 1302.03, on or before the effective date established in the final order for the transfer or addition.
[62 FR 13958, Mar. 24, 1997]
|
|
|
Sec. 1302.06 Sealing of controlled substances.
|
|
On each bottle, multiple dose vial, or other commercial container of any controlled substance, there shall be securely affixed to the stopper, cap, lid, covering, or wrapper or such container a seal to disclose upon inspection any tampering or opening of the container.
[62 FR 13958, Mar. 24, 1997]
|
|
|
Sec. 1302.07 Labeling and packaging requirements for imported and exported substances.
|
|
(a) The symbol requirements of §§ 1302.03 through 1302.05 apply to every commercial container containing, and to all labeling of, controlled substances imported into the customs territory of the United States from any place outside thereof (but within the United States), or imported into the United States from any place outside thereof.
(b) The symbol requirements of §§ 1302.03 through 1302.05 do not apply to any commercial containers containing, or any labeling of, a controlled substance intended for export.
(c) The sealing requirements of § 1302.06 apply to every bottle, multiple dose vial, or other commercial container of any controlled substance listed in schedule I or II, or any narcotic controlled substance listed in schedule III or IV imported into the customs territory of the United States from any place outside thereof (but within the United States), or imported into the United States from any place outside thereof. The sealing requirements of § 1302.06 apply to every bottle, multiple dose vial, or other commercial container of any controlled substance listed in schedule I or II, or any narcotic controlled substance listed in schedule III or IV, exported or intended for export from the United States. These sealing and labeling requirements are in addition to any sealing requirements required under applicable customs laws.
[81 FR 97020, Dec. 30, 2016]
|
|
|
Sec. 1302.08 False labeling of anabolic steroids.
|
|
(a) It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).
(b)(1) A product described in paragraph (b)(2) of this section is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this section if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq. ).
(2) A product is described in this paragraph (b)(2) if the product -
(i) Is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b), (j)); or
(ii) Is exempt from the provisions of section 505 of the Federal Food, Drug, and Cosmetic Act relating to new drugs because -
(A) It is intended solely for investigational use as described in section 505(i) of the Federal Food, Drug, and Cosmetic Act; and
(B) Such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.
[88 FR 50040, Aug. 1, 2023]
|
|
|
Authority: 21 U.S.C. 821, 825, 871(b), 958(e).
Source: 36 FR 7785, Apr. 24, 1971, unless otherwise noted. Redesignated at 38 FR 26609, Sept. 24, 1973.
|
|
